

06-23-06

IFW

CASE ON/4-32556A

FILING BY "EXPRESS MAIL" UNDER 37 CFR 1.10

EV727274104 US  
Express Mail Label Number

June 21, 2006  
Date of Deposit



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE PCT NATIONAL STAGE APPLICATION OF  
MARGARET HAN DUGAN

INTERNATIONAL APPLICATION NO: PCT/EP03/06848

FILED: 27 JUNE 2003

U.S. APPLICATION NO: 10/518,989

35 USC §371 DATE: 21 JULY 2005

FOR: COMBINATION COMPRISING A VASCULOSTATIC COMPOUND  
AND AN ALKYLATING AGENT FOR THE TREATMENT OF A  
TUMOR

**MS: Amendment**

Commissioner for Patents  
PO Box 1450  
Alexandria, VA 22313-1450

INFORMATION DISCLOSURE STATEMENT

Sir:

Applicant believes this paper is being filed before the mailing date of a first Office action on the merits, and so under 37 C.F.R. §1.97(b)(3) no fees are required. If a fee is deemed to be required, the Commissioner is hereby authorized to charge such fee to Deposit Account No. 19-0134.


In accordance with 37 C.F.R. §1.56, applicant wishes to call the Examiner's attention to the references cited on the attached form(s) PTO-1449.

The asterisked references were cited in the International Search Report and since copies of said references were forwarded by the International Bureau, only copies of the non-asterisked references are enclosed.

The Examiner is requested to consider the foregoing information in relation to this application and indicate that each reference was considered by returning a copy of the initialed PTO 1449 form(s).

Respectfully submitted,


Novartis  
Corporate Intellectual Property  
One Health Plaza, Building 104  
East Hanover, NJ 07936-1080  
(862) 778-7898

  
Lydia T. McNally  
Attorney for Applicant  
Reg. No. 36,214

Date: June 21, 2006

## INFORMATION DISCLOSURE CITATION

(Use several sheets if necessary)

ATTY. DOCKET NO.  
ON/4-32556A  
APPLICATION NO.  
10/518,989  
APPLICANT  
MARGARET HAN DUGAN  
FILING DATE  
JULY 21, 2005

Group

## U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE
/CA/	AA	* 6,258,812 B1	07/10/01	Bold et al.	514	252.03	02/11/98
	AB						
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						
	AL						

## FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	OFFICE	CLASS	SUBCLASS	TRANSLATION YES NO	
/CA/	AM	* WO 02/076926	10/03/02	WIPO			<input type="checkbox"/>	<input type="checkbox"/>
/CA/	AN	* WO 02/090346	11/14/02	WIPO			<input type="checkbox"/>	<input type="checkbox"/>
/CA/	AO	* WO 03/031440	04/17/03	WIPO			<input type="checkbox"/>	<input type="checkbox"/>
	AP						<input type="checkbox"/>	<input type="checkbox"/>
	AQ						<input type="checkbox"/>	<input type="checkbox"/>

## OTHER DOCUMENTS (Including Author, Title, Date, Pertinent pages, Etc.)

/CA/	AR	* Bocci et al., "Antitumor Activity of SU5416 in Association with Gemcitabine In Vitro and in Mice Bearing MIA PaCa-2 Human Pancreas Adenocarcinoma", <i>Pancreas</i> , Vol. 21, No. 4, p. 432 (2000).
/CA/	AS	* Browder et al., "Antiangiogenic Scheduling of Chemotherapy Improves Efficacy against Experimental Drug-resistant Cancer", <i>Cancer Res</i> , Vol. 60, No. 7, pp. 1878-1886 (2001).
/CA/	AT	Chan et al., "Expression of Vascular Endothelial Growth Factor and Its Receptors in the Anaplastic Progression of Astrocytoma, Oligodendroglioma, and Ependymoma", <i>Am J Surg Pathol</i> , Vol. 22, No. 7, pp. 816-826 (1998).

EXAMINER

/Charanjit Aulakh/

DATE CONSIDERED

05/21/2008

\*EXAMINER: Initial of reference considered, whether or not citation is in conformance with MPEP 609: Draw a line through citation if not in conformance and not considered. Include a copy of this form with the next communication to applicant.

## INFORMATION DISCLOSURE CITATION

(Use several sheets if necessary)

ATTY. DOCKET NO.  
ON/4-32556A  
APPLICATION NO.  
10/518,989  
APPLICANT  
MARGARET HAN DUGAN  
FILING DATE  
JULY 21, 2005

Group

EXAMINER  
INITIAL

## OTHER DOCUMENTS (Including Author, Title, Date, Pertinent pages, Etc.)

/CA/	DA	Cheng et al., "Suppression of Glioblastoma Angiogenicity and Tumorigenicity by Inhibition of Endogenous Expression of Vascular Endothelial Growth Factor", <i>Proc Natl Acad Sci USA</i> , Vol. 93, No. 16, pp. 8502-8507 (1996).
/CA/	DB	Im et al., "Antiangiogenesis Treatment for Gliomas: Transfer of Antisense-Vascular Endothelial Growth Factor Inhibits Tumor Growth <i>In Vivo</i> ", <i>Cancer Res</i> , Vol. 59, No. 4, pp. 895-900 (1999).
/CA/	DC	* Kato et al., "Enhanced Suppression of Tumor Growth by Combination of Angiogenesis Inhibitor O-(chloroacetyl-carbamoyl)fumagillol (TNP-470) and Cytotoxic Agents in Mice", <i>Cancer Res</i> , Vol. 54, No. 19, pp. 5143-5147 (1994).
/CA/	DD	Kim et al., "Inhibition of Vascular Endothelial Growth Factor-induced Angiogenesis Suppresses Tumour Growth <i>In Vivo</i> ", <i>Nature</i> , Vol. 362, No. 6423, pp. 841-844 (1993).
/CA/	DE	* Lin et al., "The Vascular Endothelial Growth Factor Receptor Tyrosine Kinase Inhibitor PTK787/ZK222584 Inhibits Growth and Migration of Multiple Myeloma Cells in the Bone Marrow Microenvironment", <i>Cancer Res</i> , Vol. 62, No. 17, pp. 5019-5026 (2002).
/CA/	DF	* Ma et al., "Pharmacodynamic-mediated Reduction of Temozolomide Tumor Concentrations by the Angiogenesis Inhibitor TNP-470", <i>Cancer Res</i> , Vol. 61, No. 14, pp. 5491-5498 (2001).
/CA/	DG	* Mehta et al., "Radiation Therapy Oncology Group. Research Plan 2002-2006. Brain Tumor Committee", <i>Int J Radiat Oncol Biol Phys</i> , Vol. 51, No. 3, Suppl. 2, pp. 11-18 (2001).
/CA/	DH	Millauer et al., "Glioblastoma Growth Inhibited <i>In Vivo</i> by a Dominant-negative Flk-1 Mutant", <i>Nature</i> , Vol. 367, No. 6463, pp. 576-579 (1994).
/CA/	DI	* Newton, "Novel Chemotherapeutic Agents for the Treatment of Brain Cancer", <i>Expert Opin Investig Drugs</i> , Vol. 9, No. 12, pp. 2815-2829 (2000).
/CA/	DJ	Oehring et al., "Vascular Endothelial Growth Factor (VEGF) in Astrocytic Gliomas – A Prognostic Factor?", <i>J Neuro-Oncol</i> , Vol. 45, pp. 117-125 (1999).
/CA/	DK	Plate et al., "Vascular Endothelial Growth Factor is a Potential Tumour Angiogenesis Factor in Human Gliomas <i>In Vivo</i> ", <i>Nature</i> , Vol. 359, No. , pp. 845-848 (1992).
/CA/	DL	* Rosen, "Angiogenesis Inhibition in Solid Tumors", <i>Cancer J</i> , Vol. 7, Suppl. 3, pp. S120-S128 (2001).
/CA/	DM	Takano et al., "Concentration of Vascular Endothelial Growth Factor in the Serum and Tumor Tissue of Brain Tumor Patients", <i>Cancer Res</i> , Vol. 56, No. 9, pp. 2185-2190 (1996).
/CA/	DN	* Teicher et al., "Comparison of Several Antiangiogenic Regimens Alone and With Cytotoxic Therapies in the Lewis Lung Carcinoma", <i>Cancer Chemther Pharmacol</i> , Vol. 38, No. 2, pp. 169-177 (1996).
/CA/	DO	Weindel, Moringlane, Marme and Weich, "Detection and Quantification of Vascular Endothelial Growth Factor/Vascular Permeability Factor in Brain Tumor Tissue and Cyst Fluid: The Key to Angiogenesis?", <i>Neurosurgery</i> , Vol. 35, No. 3, pp. 439-449 (1994).

EXAMINER

/Charanjit Aulakh/

DATE CONSIDERED

05/21/2008

\*EXAMINER: Initial of reference considered, whether or not citation is in conformance with MPEP 609: Draw a line through citation if not in conformance and not considered. Include a copy of this form with the next communication to applicant.